Related Experiment Video
Updated: Jan 21, 2026

Spatiotemporal Control of Protein Activity through Optogenetic Allosteric Regulation
Published on: October 4, 2024
Activation of Caspase-6 Is Promoted by a Mutant Huntingtin Fragment and Blocked by an Allosteric Inhibitor Compound
Dagmar E Ehrnhoefer1, Niels H Skotte1, Jeanette Reinshagen2
1Centre for Molecular Medicine and Therapeutics (CMMT), Department of Medical Genetics, University of British Columbia, 950 West 28th Avenue, Vancouver, BC V5Z 4H4, Canada.
Insights
Aberrant caspase-6 (C6) activation drives Huntington disease (HD) pathogenesis. A C6-cleaved fragment of mutant huntingtin (mHTT) stabilizes C6, creating a self-amplifying cycle that a novel inhibitor can disrupt.
Area of Science:
- Neuroscience
- Biochemistry
- Molecular Biology
Background:
- Aberrant caspase-6 (C6) activation occurs in Huntington disease (HD) without typical apoptosis hallmarks.
- C6 activity correlates with HD progression, and cleavage of mutant huntingtin (mHTT) is implicated in pathogenesis.
Purpose of the Study:
- To investigate the mechanism by which C6 contributes to HD pathogenesis.
- To identify potential therapeutic targets for disrupting the C6-mHTT interaction.
Main Methods:
- Biochemical assays to study C6 and mHTT interactions.
- Molecular docking to analyze inhibitor binding.
- Cellular and animal models of Huntington disease.
Main Results:
- The mHTT1-586 fragment generated by C6 cleavage interacts with C6 zymogen.
- This interaction stabilizes an active conformation of C6, promoting further activation.
- A small-molecule inhibitor blocks the C6-mHTT1-586 interaction, preventing enhanced C6 activity.
Conclusions:
- The interaction between mHTT1-586 and C6 zymogen forms a feedforward loop, driving HD pathogenesis.
- Inhibiting this interaction offers a potential therapeutic strategy for Huntington disease.
Abstract:
Aberrant activation of caspase-6 (C6) in the absence of other hallmarks of apoptosis has been demonstrated in cells and tissues from patients with Huntington disease (HD) and animal models. C6 activity correlates with disease progression in patients with HD and the cleavage of mutant huntingtin (mHTT) protein is thought to strongly contribute to disease pathogenesis. Here we show that the mHTT1-586 fragment generated by C6 cleavage interacts with the zymogen form of the enzyme, stabilizing a conformation that contains an active site and is prone to full activation. This shift toward enhanced activity can be prevented by a small-molecule inhibitor that blocks the interaction between C6 and mHTT1-586. Molecular docking studies suggest that the inhibitor binds an allosteric site in the C6 zymogen. The interaction of mHTT1-586 with C6 may therefore promote a self-reinforcing, feedforward cycle of C6 zymogen activation and mHTT cleavage driving HD pathogenesis.
Related Concept Videos
Cooperative Allosteric Transitions
Cooperative Allosteric Transitions
Mass Spectrometry: Aromatic Compound Fragmentation
Habitat Fragmentation
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Caspases

